The Israel Cancer Research Fund (ICRF) will host its 2012 Tower of Hope Gala on December 3 at the Pierre Hotel at 2 East 61st Street in New York City. The evening’s honored guests will be oncologist Dr. Yashar Hirshaut, who will receive the Tower of Hope lifetime achievement award, and Peter and Mary Max who will be accepting the Tower of Hope humanitarian award for philanthropic leadership and service. Benjamin Brafman will serve as master of ceremonies.
Dr. Yashar Hirshaut, a renowned oncologist and resident of Long Island, has dedicated his life to fighting the war against cancer. In addition to his private practice, Dr. Hirshaut is an attending physician at Lenox Hill Hospital, Beth Israel Hospital, New York Hospital, and Mt. Sinai Medical Center. He authored the book, Breast Cancer: The Complete Guide, as well as founded and edited the journal, Cancer Investigation. Dr. Hirshaut is president and chairman emeritus of ICRF and was recently appointed president of the Israel Cancer Research Fund International Scientific Council.
Peter Max has a long-standing career as the preeminent Pop artist in America. With paintings on exhibition in hundreds of museums and galleries worldwide, his vibrant colors have become part of contemporary culture. Peter Max has painted for many heads of state, including six U.S. presidents. From art that appeared on the first U.S. 10-cent stamp bearing the title, Preserve the Environment, to 235 U.S. Border murals greeting millions of people entering America each year, Peter Max seeks to capture themes of America in his art. Together with his wife Mary, Peter is an ardent supporter of animal rights.
The evening will begin at 6:00 p.m. with a reception, silent and Chinese auctions, followed by dinner and an awards ceremony. Tickets are $600 per person. For more information, please contact Shoshana Ellihou, New York director of development, at 212-969-9800, ext. 225 or Shoshana.firstname.lastname@example.org.
According to Bradley Goldhar, president of ICRF, “ICRF has identified and funded world class cancer research scientists working in Israel. The organization is focused on funding both established scientists and young researchers who are just starting their careers. Our targeted funding has helped lead to the discovery of significant cancer fighting drugs such as Doxil, Gleevec, and Velcade. These drugs are helping thousands of cancer patients in North America and around the world.”
The Israel Cancer Research Fund is the single largest source of private funds for cancer research in Israel. Since its establishment in 1975, it has provided more that 1,937 grants totaling $45,795,000 to outstanding scientists who work at all of the leading research institutions in Israel. The scientists include two recipients of the Nobel Prize in Chemistry and an awardee of the prestigious G.H.A. Clowes award from the American Research Association.